This is a trivalent influenza vaccine (split virion, inactivated).
The content of this package leaflet has been prepared in the assumption that it will be read by the person receiving the vaccine. However, since this vaccine may be administered to adults and children, it is possible that the content of the package leaflet will be reviewed by a parent or guardian of the child.
Fluarix is a vaccine intended for use in adults and children from 6 months of age to prevent influenza.
Influenza is a disease of the upper respiratory tract and lungs caused by the influenza virus. The most common symptoms of influenza are high temperature, sore throat, cough, general aches and pains, headache, weakness, and fatigue. Post-influenza complications can occur, especially in very young, older, and immunocompromised individuals.
Before administering Fluarix, discuss with your doctor, pharmacist, or nurse:
After or even before administration of each injection, fainting (especially in adolescents) may occur. Inform your doctor, pharmacist, or nurse if the patient has fainted during injection in the past.
If the patient has weakened immune systems, e.g., due to HIV infection or immunosuppressive therapy, Fluarix may not be fully effective.
Tell your doctor, pharmacist, or nurse if any of the above applies to the person to be vaccinated or if the patient is unsure.
Tell your doctor, pharmacist, or nurse about all medicines being taken now or recently, and any medicines planned to be taken.
Inform about any recently administered vaccines.
If Fluarix is administered at the same time as other vaccines, each vaccine should be administered at a different injection site.
If the patient is pregnant or breastfeeding, thinks they may be pregnant, or plans to have a baby, they should consult their doctor or pharmacist before using this vaccine.
Some of the effects mentioned below in section 4 "Possible side effects" (e.g., fatigue or dizziness) may temporarily affect the ability to drive or operate machinery.
Do not drive or operate machinery if the patient does not feel well.
This vaccine contains less than 1 mmol of sodium (23 mg) per dose, which is considered "sodium-free".
This vaccine contains potassium, less than 1 mmol (39 mg) per dose, which is considered "potassium-free".
This vaccine contains no more than 0.415 mg of polysorbate 80 per dose. Polysorbates may cause allergic reactions. Consult a doctor if the patient is allergic to this substance.
Fluarix is administered as a single intramuscular injection of 0.5 ml.
Children under 9 years of age who have not been previously vaccinated against influenza should receive a second dose at least 1 month after the first dose. Ensure the child receives all doses of the vaccine to achieve better protection against influenza.
For further questions on the use of this vaccine, consult a doctor, pharmacist, or nurse.
Like all medicines, this vaccine can cause side effects, although not everybody gets them.
For further information on possible side effects of Fluarix, consult a doctor, pharmacist, or nurse.
Tell your doctor immediately if the patient experiences any of the following severe side effects; urgent medical attention may be needed.
Rare:may occur in up to 1 in 1,000 doses of the vaccine
Tell your doctor, pharmacist, or nurse if the patient experiences any of the following side effects.
Rare:may occur in up to 1 in 1,000 doses of the vaccine
Very common:may occur in more than 1 in 10 doses of the vaccine
Common:may occur in up to 1 in 10 doses of the vaccine
Very common:may occur in more than 1 in 10 doses of the vaccine
Common:may occur in up to 1 in 10 doses of the vaccine
Very common:may occur in more than 1 in 10 doses of the vaccine
Common:may occur in up to 1 in 10 doses of the vaccine
Rare:may occur in up to 1 in 100 doses of the vaccine
If side effects occur, including any not listed in the package leaflet, tell your doctor or pharmacist. Side effects can be reported directly to the Department of Drug Adverse Reaction Monitoring of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw, tel.: +48 22 49 21 301, fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl.
By reporting side effects, you can help provide more information on the safety of this medicine.
Side effects can also be reported to the marketing authorization holder.
The active substance is split, inactivated influenza virus from the following strains*:
15 micrograms of HA**
15 micrograms of HA**
15 micrograms of HA**
in a 0.5 ml dose
* grown in fertilized eggs from healthy flocks
** hemagglutinin
This vaccine is in line with the recommendations of the World Health Organization (WHO) (for the Northern Hemisphere) and the European Union for the 2025/2026 season.
Other ingredients of the vaccine are: sodium chloride, disodium phosphate dodecahydrate, potassium dihydrogen phosphate, potassium chloride, magnesium chloride hexahydrate, α-tocopherol hydrogen succinate, polysorbate 80, octoxynol 10, and water for injections.
GlaxoSmithKline Biologicals S.A.
GlaxoSmithKline Biologicals
Rue de l’Institut 89
SmithKline Beecham Pharma GmbH&Co. KG
1330 Rixensart
Zirkusstrasse 40
Belgium
01069 Dresden
Germany
Member State | Name |
Austria | Fluarix Trivalent |
Belgium, Luxembourg | Alpharix |
Finland, France, Spain, Netherlands, Norway, Poland, Portugal, Sweden, Italy | Fluarix |
Greece, Germany | Influsplit |
Detailed information on this medicine is available on the website of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products.
---------------------------------------------------------------------------------------------------------------------------
Information intended for healthcare professionals only:
Before administration, inspect the vaccine for any visible signs of damage or physical changes.
Shake before use to obtain a colorless to slightly opalescent liquid. If any changes are observed, do not administer the vaccine.
Administer the entire contents of the pre-filled syringe.
Instructions for the pre-filled syringe
Hold the pre-filled syringe by the body, not by the plunger.
Luer Lock adapter
Twist the needle hub of the pre-filled syringe in a counter-clockwise direction to remove it.
Plunger
Body
Needle hub
Attach the needle to the pre-filled syringe by twisting the needle hub onto the Luer Lock adapter (LLA) in a clockwise direction until it clicks into place.
Do not pull the plunger out of the body of the pre-filled syringe. If this happens, do not administer the vaccine.
Needle hub
Disposal
Any unused product or waste material should be disposed of in accordance with local requirements.
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.